论文部分内容阅读
AIM To evaluate the clinical outcomes of 240-wktreatment with entecavir (0.5 mg) in Chinese nucleosidenaivepatients with cirrhosis.METHODS: A total of 204 nucleoside-naive patientswith compensated (n = 96) or decompensated (n =108) hepatitis B virus (HBV)